FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200430215> ?p ?o ?g. }

• W4200430215 endingPage "9" @default.
• W4200430215 startingPage "1" @default.
• W4200430215 abstract "Personal payments from the pharmaceutical industry to US physicians are common and are associated with changes in physicians' clinical practice and interpretation of clinical trial results. We assessed temporal trends in industry payments to oncologists, with particular emphasis on payments to authors of oncology clinical practice guideline and on payments related to immunotherapy drugs.We included US physicians with active National Plan and Provider Enumeration System records and demographic data available in the Centers for Medicare & Medicaid Services Physician Compare system who had a specialty type of medical oncology or general internal medicine. Medical oncologists serving on NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Panels were identified manually. Industry payments, and the subset associated with PD-1/PD-L1 drugs, were identified in Open Payments, the federal repository of all transactions of financial value from industry to physicians and teaching hospitals, from 2014 to 2017.There were 13,087 medical oncologists and 85,640 internists who received payments. The mean, annual, per-physician value of payments to oncologists increased from $3,811 in 2014 to $5,854 in 2017, and from $444 to $450 for internists; the median payment increased from $152 to $199 for oncologists and remained at $0 for internists. Oncologists who served on NCCN Guidelines Panels received a greater value in payments and experienced a greater relative increase: mean payments increased from $10,820 in 2014 to $18,977 in 2017, and median payments increased from $500 to $1,366. Among companies marketing PD-1/PD-L1 drugs, mean annual per-oncologist payments associated with PD-1/PD-L1 drugs increased from $28 to $773. Total per-oncologist payments from companies marketing PD-1/PD-L1 drugs experienced a 165% increase from 2014 to 2017, compared with a 31% increase among similar companies not marketing PD-1/PD-L1 drugs.Pharmaceutical industry payments increased for US oncologists from 2014 to 2017 more than for general internists. The increase was greater among oncologists contributing to clinical practice guidelines and among pharmaceutical companies marketing PD-1/PD-L1 drugs. The increasing flow of money from industry to US oncologists supports ongoing concern regarding commercial interests in guideline development and clinical decision-making." @default.
• W4200430215 created "2021-12-31" @default.
• W4200430215 creator A5004599737 @default.
• W4200430215 creator A5010715186 @default.
• W4200430215 creator A5017382091 @default.
• W4200430215 creator A5084161572 @default.
• W4200430215 date "2021-12-29" @default.
• W4200430215 modified "2023-10-15" @default.
• W4200430215 title "Increasing Financial Payments From Industry to Medical Oncologists in the United States, 2014–2017" @default.
• W4200430215 cites W1519265258 @default.
• W4200430215 cites W1964644957 @default.
• W4200430215 cites W1991414891 @default.
• W4200430215 cites W2044122422 @default.
• W4200430215 cites W2111198130 @default.
• W4200430215 cites W2131233580 @default.
• W4200430215 cites W2217176171 @default.
• W4200430215 cites W2293638970 @default.
• W4200430215 cites W2343295136 @default.
• W4200430215 cites W2346692005 @default.
• W4200430215 cites W2398752996 @default.
• W4200430215 cites W2465483973 @default.
• W4200430215 cites W2471866151 @default.
• W4200430215 cites W2512541255 @default.
• W4200430215 cites W2521578066 @default.
• W4200430215 cites W2605615018 @default.
• W4200430215 cites W2610245324 @default.
• W4200430215 cites W2610800273 @default.
• W4200430215 cites W2754072979 @default.
• W4200430215 cites W2777898394 @default.
• W4200430215 cites W2796858408 @default.
• W4200430215 cites W2802547852 @default.
• W4200430215 cites W2808677260 @default.
• W4200430215 cites W2884278038 @default.
• W4200430215 cites W2894889759 @default.
• W4200430215 cites W2895825121 @default.
• W4200430215 cites W2897584864 @default.
• W4200430215 cites W2911391686 @default.
• W4200430215 cites W2911495617 @default.
• W4200430215 cites W2946889810 @default.
• W4200430215 cites W2947238107 @default.
• W4200430215 cites W2947451630 @default.
• W4200430215 cites W2954676106 @default.
• W4200430215 cites W2964448043 @default.
• W4200430215 cites W2973437744 @default.
• W4200430215 cites W3091421384 @default.
• W4200430215 cites W592159461 @default.
• W4200430215 doi "https://doi.org/10.6004/jnccn.2021.7024" @default.
• W4200430215 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34965511" @default.
• W4200430215 hasPublicationYear "2021" @default.
• W4200430215 type Work @default.
• W4200430215 citedByCount "2" @default.
• W4200430215 countsByYear W42004302152022 @default.
• W4200430215 countsByYear W42004302152023 @default.
• W4200430215 crossrefType "journal-article" @default.
• W4200430215 hasAuthorship W4200430215A5004599737 @default.
• W4200430215 hasAuthorship W4200430215A5010715186 @default.
• W4200430215 hasAuthorship W4200430215A5017382091 @default.
• W4200430215 hasAuthorship W4200430215A5084161572 @default.
• W4200430215 hasBestOaLocation W42004302151 @default.
• W4200430215 hasConcept C10138342 @default.
• W4200430215 hasConcept C126322002 @default.
• W4200430215 hasConcept C143998085 @default.
• W4200430215 hasConcept C144133560 @default.
• W4200430215 hasConcept C145097563 @default.
• W4200430215 hasConcept C160735492 @default.
• W4200430215 hasConcept C162324750 @default.
• W4200430215 hasConcept C194828623 @default.
• W4200430215 hasConcept C20387591 @default.
• W4200430215 hasConcept C2776534028 @default.
• W4200430215 hasConcept C2779974597 @default.
• W4200430215 hasConcept C50522688 @default.
• W4200430215 hasConcept C512399662 @default.
• W4200430215 hasConcept C71924100 @default.
• W4200430215 hasConceptScore W4200430215C10138342 @default.
• W4200430215 hasConceptScore W4200430215C126322002 @default.
• W4200430215 hasConceptScore W4200430215C143998085 @default.
• W4200430215 hasConceptScore W4200430215C144133560 @default.
• W4200430215 hasConceptScore W4200430215C145097563 @default.
• W4200430215 hasConceptScore W4200430215C160735492 @default.
• W4200430215 hasConceptScore W4200430215C162324750 @default.
• W4200430215 hasConceptScore W4200430215C194828623 @default.
• W4200430215 hasConceptScore W4200430215C20387591 @default.
• W4200430215 hasConceptScore W4200430215C2776534028 @default.
• W4200430215 hasConceptScore W4200430215C2779974597 @default.
• W4200430215 hasConceptScore W4200430215C50522688 @default.
• W4200430215 hasConceptScore W4200430215C512399662 @default.
• W4200430215 hasConceptScore W4200430215C71924100 @default.
• W4200430215 hasLocation W42004302151 @default.
• W4200430215 hasLocation W42004302152 @default.
• W4200430215 hasLocation W42004302153 @default.
• W4200430215 hasOpenAccess W4200430215 @default.
• W4200430215 hasPrimaryLocation W42004302151 @default.
• W4200430215 hasRelatedWork W1974171884 @default.
• W4200430215 hasRelatedWork W1974242956 @default.
• W4200430215 hasRelatedWork W2031296182 @default.
• W4200430215 hasRelatedWork W2145833305 @default.
• W4200430215 hasRelatedWork W2150198561 @default.
• W4200430215 hasRelatedWork W2281130122 @default.

• next